



Part A. PERSONAL INFORMATION

CV date

20/06/2019

First and Family name	Guillermo Velasco Díez		
Social Security, Passport, ID number	50443341V	Age	49
Researcher numbers	Researcher ID	H-5260-2012	
	Author ID	"Velasco, Guillermo" 7006478965	
	ORCID code	0000-0002-1994-2386	

A.1. Current position

Name of University/Institution	Universidad Complutense de Madrid		
Department	Bioquímica y Biología Molecular I		
Address and Country	F. Biología Edificio B, Calle José Antonio Nováis 12, 28040-Madrid		
Phone number	913945034	E-mail	gvelasco@ucm.es
Current position	Associate Professor (Profesor Titular de Universidad)	From	02/02/2008
UNESCO code			
Key words	Cell signaling, Autophagy, Cancer, Cannabinoids, Sphingolipids,		

A.2. Education

Degree/PhD	University	Year
BsC and MSc in Biology	Universidad Complutense de Madrid	1993
PhD Biology	Universidad Complutense de Madrid	1997

A.3. JCR articles, h Index, thesis supervised...

Number of 6 years research periods "sexenios de Investigación": 4 (1994-1999; 2000-2005; 2006-2011; 2012-2017). Date of the last "sexenio" granted: 2018
 Number of PhD thesis supervised: 5 (4 in the last 10 years) (+ 5 under development)
 Total citations (WoS): 9984 (years: number of citations): 2018: >1300; 2017: >1400; 2016 >1200; 2015: >900; 2014: >700); **h index (WoS): 40; h-index (Scopus): 40**
 Total JCR publications: 86; First decile publications (D1): 25; First quartile publications (Q1 - D1): 38; Publications as "corresponding/senior author": 29

Part B. CV SUMMARY (max. 3500 characters, including spaces)

Guillermo studied Biology (1988-1993) and carried out his doctoral thesis in the Department of Biochemistry and Molecular Biology I of the Faculty of Chemical Sciences of the Complutense University under the direction of Dr. Manuel Guzmán (1994-1997) in the topic: Mechanisms of regulation of fatty acid oxidation in rat liver). Later he made a post-doctoral stay in the laboratory of Dr. Philip Cohen (1998-1999) at the University of Dundee, Scotland where he studied the role of Rho Kinase in the regulation of smooth muscle contraction and became familiar with molecular biology techniques and the study. of cell signaling mechanisms.

In 1999 he rejoined the Department of Biochemistry and Molecular Biology I as Assistant Professor, later obtaining a position as "Professor Contratado Doctor" (2003). Since February 2008, Guillermo Velasco is Associate Professor ("Profesor Titular de Universidad") of the Department of Biochemistry and Molecular Biology I of the Complutense University of Madrid. Starting in 2001 and within the Cannabinoid Signaling Group, Guillermo Velasco has been developing a line of research focused on the study of the molecular mechanisms underlying the anti-tumor action of cannabinoids, as well as on the optimization of the conditions of use of these agents for their possible clinical application.

The results of the studies developed by the group coordinated by Guillermo Velasco have been published in some of the most important journals in the field of cancer research (for example Cancer Cell, Cancer Research, Journal of Clinical Investigation, Cell Death and Differentiation or Nature Reviews Cancer) have generated three patents and have laid the groundwork for the development of a clinical trial (based on the combined administration of the drug Sativex



in combination with temozolomide to patients with GBM) promoted by the company GW pharma ltd: (NCT01812616)

Likewise, the results of the group have led to lay the foundations of another clinical trial in which the drug Crizotinib is administered in combination with TMZ and Radiotherapy to patients with GBM (NCT02270034).

Currently the group coordinated by Guillermo Velasco consists of one senior researchers, 1 postdoctoral researcher, 4 PhD students (supported by i-P-FIS (1), FPU (1) and Marie Sklowdoska Curie (2) grants respectively), 1 Ayudante de investigación (Supported by FGJ CAM), 1 Master student and 1 technicians The main projects of the group are: (i) the role of autophagy in cancer; (ii) the role of the Midkine / ALK axis in the generation of gliomas (iii) the study of the anti-tumoral action of cannabinoids in gliomas and other types of tumors and (iv) the role of Tribbles pseudokinase in cancer.

Likewise, the Group of Guillermo Velasco is a consolidated group in the area of Oncology at the "Instituto de Investigaciones sanitarias San Carlos" associated with the Hospital Clínico San Carlos. Since year 2019, Guillermo is the leader of Oncology translational clinical Research at Hospital Clínico Sab Carlos

Part C. RELEVANT MERITS

C.1. Publications (including books) (10 most relevant publications)

- 1) López-Valero I, Saiz-Ladera C, Torres S, Hernández-Tiedra S, García-Taboada E, Rodríguez-Fornés F, Barba M, Dávila D, Salvador-Tormo N, Guzmán M, Sepúlveda JM, Sánchez-Gómez P, Lorente M, **Velasco G**
Targeting Glioma Initiating Cells with a combined therapy of cannabinoids and temozolomide
Biochem. Pharmacol. 157, 266-274 (2018) IF (2017): 4,235 (Q1)
- 2) Hernández-Tiedra S, Fabriàs G, Dávila D, Salanueva ÍJ, Casas J, Montes LR, Antón Z, García-Taboada E, Salazar-Roa M, Lorente M, Nylandsted J, Armstrong J, López-Valero I, McKee CS, Serrano-Puebla A, García-López R, González-Martínez J, Abad JL, Hanada K, Boya P, Goñi F, Guzmán M, Lovat P, Jäättelä M, Alonso A, **Velasco G**.
Dihydroceramide accumulation mediates cytotoxic autophagy of cancer cells via autolysosome destabilization
Autophagy. 12 2213-2229 (2016) IF (2016): 8.593 (Q1)
- 3) Armstrong, JL, Hill, DS, McKee, CS Hernandez-Tiedra, S, Lorente M, Lopez-Valero I, Anagnostou, ME, Babatunde, F, Corazzari, M, Redfern CPF, **Velasco, G***, Penny E Lovat
Exploiting cannabinoid-induced cytotoxic autophagy to drive melanoma cell death
J Invest Dermatol. 135: 1629-1637 (2015) IF (2014): 6.915 (D1)
*(GV and PL co-senior authors)
- 4) Cianfanelli V, Fuoco C, Lorente M, Salazar M, Quondamatteo F, Gherardini PF, De Zio D, Nazio F, Antonioli M, D'Orazio M, Skobo T, Bordi M, Rohde M, Dalla Valle L, Helmer-Citterich M, Gretzmeier C, Dengjel J, Fimia GM, Piacentini M, Di Bartolomeo S, **Velasco G**, Cecconi F.
"AMBRA1 links autophagy to cell proliferation and tumorigenesis by promoting c-MYC dephosphorylation and degradation" by promoting c-MYC dephosphorylation and degradation
Nat Cell Biol. 17:20-30 (2015) IF (2015): 18.699 (D1)
- 5) Salazar M, Lorente M, García-Taboada E, Pérez Gómez E, Dávila D, Zúñiga-García P, María Flores J, Rodríguez A, Hegedus Z, Mosén-Ansorena D, Aransay AM, Hernández-Tiedra S, López-Valero I, Quintanilla M, Sánchez C, Iovanna JL, Duseti N, Guzmán M, Francis SE, Carracedo A, Kiss-Toth E, **Velasco G**. *Loss of Tribbles pseudokinase-3 promotes Akt-driven tumorigenesis via FOXO inactivation*
Cell Death Differ. 22: 131-44 (2015) IF (2015): 8.218 (D1)



- 6) Velasco, G*, Sánchez, C & Guzmán, M "Towards the use of cannabinoids as anti-tumour agents"
Nat Rev Cancer 12, 436-44. (2012) IF (2012): 35.0 (D1)
*GV (Corresponding author)
- 7) Vara D, Salazar M, Olea-Herrero N, Guzmán M, *Velasco G, *Díaz-Laviada I. *Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy.*
Cell Death Differ. **18**:1099-111 (2011) IF (2011): 8.849 (D1)
(*GV same contribution than ID-L)
- 8) Lorente, M., Torres, S., Salazar, M., Carracedo, A., Hernández-Tiedra, S., Rodríguez-Fornés, F., García-Taboada, E., Meléndez, B., Mollejo, M., Campos-Martín, Y., Lakatos, SA, Barcia, J., Guzmán, M. & **Velasco, G.** *Stimulation of the midkine/ALK axis renders glioma cells resistant to cannabinoid antitumoral action*
Cell Death Differ **18**:959-73 (2011) IF (2011): 8.849 (D1)
- 9) Salazar, M., Carracedo, A., Salanueva, I.J. Hernández, S., Lorente, M., Egia, A, Vázquez, P., Blázquez, C., Torres, S., García, S, Nowak, J., Fimia, G.M., Piacentini, M., Ceconi, F., Pandolfi, P.P., González-Feria, L., Iovanna, J.L., Guzmán, M., Boya, P. & **Velasco, G.** *Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells.*
J. Clin. Invest. **119**:1359-1372 (2009) IF (2009): 15.387 (D1)
- 10) Carracedo, A., Lorente, M., Egia, A., Blázquez, C., García, S., Giroux, V., Malicet, C., Villuendas, R., Gironella, M., González-Feria, L., Piris, M.A., Iovanna, J.L., Guzmán, M., **Velasco, G.** *The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells*
Cancer Cell **9**, 301-312 (2006) IF (2006): 24.077 (D1)

C.2. Research projects and grants

Guillermo Velasco has obtained financial support as principal investigator from regional, national or international calls on a continued manner for the last 17 years

Selected more recent projects:

TÍTULO OF THE PROJECT: Tribbles Research and Innovation Network (TRAIN – GA 721532)
FUNDING INSTITUTION: European Union (H2020), Marie Skłodowska-Curie Innovative Training Network (ITN)
DURATION FROM: 01/09/2016 TO: 31/08/2020
PRINCIPAL INVESTIGATOR: Endre Kiss Toth (Project coordinator)/ Guillermo Velasco (IP IdISSC-UCM group); FUNDING: 3.368.370 €/ 430.946 € IdISSC-UCM

TÍTULO OF THE PROJECT: Mechanism of autophagy-mediated cancer cell death and participation of autophagy associated genes in the control of tumorigenesis.
FUNDING INSTITUTION: MINECO/ISC III (PI18/00442)
DURATION FROM: 01/01/2019 TO: 31/12/2021
PRINCIPAL INVESTIGATOR: Guillermo Velasco; FUNDING: 153.670 €

TÍTULO OF THE PROJECT: Towards the utilization of cannabinoids as anticancer agents in gliomas
FUNDING INSTITUTION: Voices Against Brain Cancer
DURATION FROM: 03/05/2016 TO: 25/02/2019
PRINCIPAL INVESTIGATOR: Guillermo Velasco; FUNDING: 88.000 €

TÍTULO OF THE PROJECT: Role of Autophagy in cancer; Mechanism of autophagy-mediated cancer cell death and participation of autophagy associated genes in the control of tumorigenesis.



FUNDING INSTITUTION: MINECO/ISC III (PI15/00339)
DURATION FROM: 01/01/2016 TO: 31/12/2018
PRINCIPAL INVESTIGATOR: Guillermo Velasco; FUNDING: 244.420 €

TÍTULO OF THE PROJECT: Role of ORMDLs - a novel family of sphingolipid biosynthesis regulators - in cannabinoid anticancer action (15/C/2013)

FUNDING INSTITUTION: FUNDACIÓN TELEMARATÓ
DURATION FROM: 07/05/2014 TO: 31/12/2017
PRINCIPAL INVESTIGATORS: Rubén Vicente (Subproject "Universidad Pompeu Fabra") and Guillermo Velasco (Subproject IDISSC-UCM)
FUNDING: 300.000 € (150.000 € Subproject IDISSC-UCM)

C.3. Most relevant contracts with Pharmaceutical companies

TÍTULO OF THE PROJECT: Pre-clinical assessment of efficacy of midkine neutralizing antibodies in combination with cannabinoids and/or TMZ in glioma models in vivo

FUNDING INSTITUTION: Cellmid DURATION: 2015-2017

PRINCIPAL INVESTIGATOR: Guillermo Velasco Díez

FUNDING: 31.696 €

TÍTULO OF THE PROJECT: GW cannabinoids as antitumoral agents

FUNDING INSTITUTION: GW Pharmaceuticals DURATIO FROM: 2014 TO: 2016

PRINCIPAL INVESTIGATOR: Guillermo Velasco

FUNDING: 120.000 €

TÍTULO OF THE PROJECT: Optimizing cannabinoid-based anti-tumoral therapies in gliomas

FUNDING INSTITUTION: GW Pharmaceuticals DURATIO FROM: 2010 TO: 2014

PRINCIPAL INVESTIGATOR: Guillermo Velasco

FUNDING: 200.000 €

C.4. Patents

TITLE: Antitumoral effects of cannabinoids combinations

AUTHORS: Guillermo Velasco, Manuel Guzmán, Mar Lorente, Sofía Torres y Fátima Rodríguez

PROPRIETARY: GW Pharmaceuticals

TITLE: Cannabinoids in combination with non-cannabinoids chemotherapeutic agents

AUTHORS: Guillermo Velasco, Manuel Guzmán, Mar Lorente y Sofía Torres

PROPRIETARY: GW Pharmaceuticals

TITLE: Phytocannabinoids in the treatment of cancer

AUTHORS: Daniela Parolaro, et al. (G Velasco as one of the inventors)

PROPRIETARY: Otsuka

C5. Member of editorial committees: Academic Editor of Plos One from 2012, Academic editor of Caners from 2019

C6. Project/grant evaluation:

- Member of the International cooperation panel from the Flemish Research Council (FWO) from 2010

- Frequent reviewer for ANEP (since 2010) and for several regional, national and international agencies as well as for different private Foundations

C7. Other research and administrative activities

- Member of the handling commission (Comisión Delegada) of The Institute of Biomedical Research from "Hospital Clínico San Carlos"

- Leader of Working Group IV of the COST action TRANSAUTOPHAGY (<http://cost-transautophagy.eu/>)